237 related articles for article (PubMed ID: 32295420)
21. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A; Ottani A; Sandrini M
Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
23. Selective COX-2 inhibitors and risk of myocardial infarction.
Krotz F; Schiele TM; Klauss V; Sohn HY
J Vasc Res; 2005; 42(4):312-24. PubMed ID: 15976506
[TBL] [Abstract][Full Text] [Related]
24. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
25. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications.
Bergqvist F; Morgenstern R; Jakobsson PJ
Prostaglandins Other Lipid Mediat; 2020 Apr; 147():106383. PubMed ID: 31698145
[TBL] [Abstract][Full Text] [Related]
26. Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs.
Fowles RE
J Pain Palliat Care Pharmacother; 2003; 17(2):27-50. PubMed ID: 14649387
[TBL] [Abstract][Full Text] [Related]
27. Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies.
Yuhki K; Kojima F; Kashiwagi H; Kawabe J; Fujino T; Narumiya S; Ushikubi F
Pharmacol Ther; 2011 Feb; 129(2):195-205. PubMed ID: 20920529
[TBL] [Abstract][Full Text] [Related]
28. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
Hermann M; Ruschitzka F
Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
[TBL] [Abstract][Full Text] [Related]
29. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Wang M; Song WL; Cheng Y; Fitzgerald GA
J Intern Med; 2008 May; 263(5):500-5. PubMed ID: 18410593
[TBL] [Abstract][Full Text] [Related]
30. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
31. [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects].
Batlouni M
Arq Bras Cardiol; 2010 Apr; 94(4):556-63. PubMed ID: 20498929
[TBL] [Abstract][Full Text] [Related]
32. [Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers].
Ohara M; Sawa T
Masui; 1998 Nov; 47(11):1325-32. PubMed ID: 9852696
[TBL] [Abstract][Full Text] [Related]
33. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders.
Koeberle A; Werz O
Biochem Pharmacol; 2015 Nov; 98(1):1-15. PubMed ID: 26123522
[TBL] [Abstract][Full Text] [Related]
34. Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE
Hao H; Hu S; Wan Q; Xu C; Chen H; Zhu L; Xu Z; Meng J; Breyer RM; Li N; Liu DP; FitzGerald GA; Wang M
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1115-1124. PubMed ID: 29599139
[TBL] [Abstract][Full Text] [Related]
35. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation.
Padol IT; Hunt RH
Rheumatology (Oxford); 2010 May; 49(5):837-43. PubMed ID: 19779026
[TBL] [Abstract][Full Text] [Related]
36. [Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment].
Schmidt M; Fosbøl EL; Torp-Pedersen C; Olsen AS; Christensen B; Gislason GH
Ugeskr Laeger; 2016 Dec; 178(52):. PubMed ID: 28041549
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Martínez-González J; Badimon L
Curr Pharm Des; 2007; 13(22):2215-27. PubMed ID: 17691994
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of microsomal prostaglandin E-synthase-1 (mPGES-1) selectively suppresses PGE
Martin EM; Jones SL
Vet Immunol Immunopathol; 2017 Oct; 192():33-40. PubMed ID: 29042013
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2: a therapeutic target.
Turini ME; DuBois RN
Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
[TBL] [Abstract][Full Text] [Related]
40. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
